Les Newsletters de Stop-Tabac.ch

Webmasters - Proposez nos news sur votre site

Rechercher dans les anciennes newsletter:

07 novembre 2017

Le 07 Novembre 2017

Préparées par Jean-François Etter

• BAT lance glo, un produit de tabac chauffé
• E-cigarette Summit, Londres, 17 novembre 2017
• Snus saves lives - A study of snus and tobacco-related mortality in the EU
• Science Needs a Solution for the Temptation of Positive Results

BAT lance glo, un produit de tabac chauffé

La concurrence entre produits de nouvelle génération, où le tabac est chauffé et non brûlé donc à nocivité potentiellement réduite, s'avive. BAT a choisi Zurich pour lancer son dispositif sans combustion glo ...


E-cigarette Summit, Londres, 17 novembre 2017

Il est encore temps de vous inscrire au E-cigarette Summit qui ara lieu à Londres le 17 novembre prochain. Très bon programme, nombreux orateurs de haut niveau. Ce meeting est indépendant de l'industrie, les orateurs sont des scientifiques, des membres d'ONG et du gouvernement UK.
Programme et inscriptions:


Time is running out to register for this year's E-Cigarette Summit, which takes place at The Royal Society in London, on Friday 17th November.

If you would like to view the full programme please go to www.e-cigarette-summit.com

Since the inaugural meeting in November 2013, The E-Cigarette Summit has been at the forefront of taking forward the scientific and public health discussions around e-cigarettes and harm reduction debates. The Summit has established itself as a neutral environment for scientists, policy makers, medical and public health professionals and stakeholders to come together and look at the latest scientific research and evidence on e-cigarettes, and debate their impact.

This year, we welcome renowned presenters from many international communities looking at how the UK's position differs in its approach to Harm Reduction. The Summit, Chaired by Prof Ann McNeill, will examine the latest research on health impacts and explore the role of tobacco control in an increasingly diverse and innovative nicotine market. With smoking levels falling in most developed countries, the Summit will also look at the attitudes to harm reduction and its contribution to smoking cessation.

The E-Cigarette Summit provides an evidence based platform to look beyond the rhetoric and understand the issues that lie behind differing perspectives and policy positions. If you would like to have your say and join the debate, please register on-line at www.e-cigarette-summit.com

Key Topics Include:
The Tobacco Control Plan for England Tim Baxter, Department of Health
Improving the quality of research on e-cigarettes - Prof. Robert West, University College London
Values and the Continuum of Harm Reduction Prof Amy Fairchild, Texas A&M School of Public Health
A neutral assessment of The Foundation for a Smoke- Free World Prof Jean Francois Etter, University of Geneva Switzerland
Relative Risk of Cancer for Smoking, E-Cigarettes and Heat not Burn Dr Ed Stephens, University of St Andrews
Toxicant and Carcinogen exposure associated with long term e-cigarette use Dr Lion Shahab, University College London
Cardiovascular health and nicotine Dr. Konstantinos Farsalinos, University of Patras Greece
Applying the Cochrane Review gold standard to other meta data analysis on smoking cessation Jamie Hartmann-Boyce, Cochrane Tobacco Addiction Group, Oxford University
The impact of Long term e-cigarette use on lung health Prof Riccardo Poloso MD , University of Catania
Regulation of Heat not Burn versus e-cigarettes Deborah Arnott (ASH)
Regulatory Updates - MHRA and BCAP
The independent vape sector and their relationship with smokers and vapers Matthew Moden, IBVTA
A challenge to medicinal regulators in their expectations of ENDS David Graham, NJOY
The challenge of reaching current smokers Martin Dockrell, PHE & Louise Ross, Leicester City Council
The impact of e-cigarettes on smoking cessation Prof. David Levy, Georgetown University
Ethical issues raised by the Australian ban on Electronic Nicotine Devices Prof Wayne Hall, University of Queensland
Remembering the impact on human life in discussion on harm reduction Sarah Jakes, Vaper and New Nicotine Alliance

We look forward to welcoming you to The Royal Society on Friday 17th November for an engaging and stimulating day. www.e-cigarette-summit.com www.smooth-events.com

Snus saves lives - A study of snus and tobacco-related mortality in the EU

This report demonstrates the difference between the current level of tobacco-related mortality in EU countries and the level that would have been achieved had all other EU countries adopted the same tobacco consumption patterns as in Sweden. The basis for the figures in the report consists of data from the World Health Organization (WHO) Global Report: Mortality Attributable to Tobacco (Geneva, 2012). The data processing was carried out by Institutet för Tobaksstudier (Institute for Tobacco Studies) and a compilation of the data was put at our disposal. The figures refer to men over the age of thirty in each individual country and concern several groups of diseases. The report shows that Sweden has the lowest tobaccorelated mortality rate of all EU countries relative to its population size. As compared with Sweden, tobacco-related mortality rates are more than twice as high relative to population size in 24 of the other 27 EU member states.

In total and among men over the age of 30, 355,000 lives per year could have been saved if the other EU countries had matched Sweden's tobacco-related mortality rate. Sweden clearly has the lowest tobaccorelated mortality rate within the EU in relation to its population size, despite daily tobacco consumption among men being at the same level as other countries in Europe. Sweden is also the only country in the EU where snus is permitted. There is a clear connection here snus is a significantly less dangerous product than cigarettes: the difference in terms of health effects corresponds to hundreds of thousands of lives per year in Europe. Snus enables Sweden to have a uniquely low number of smokers, and it is difficult to ignore the connection between the low level of smokers and the uniquely low tobacco-related mortality rate. In other words, the tobacco-related mortality rate would have been lower across the EU today had snus been permitted within the union over the past few decades.


Science Needs a Solution for the Temptation of Positive Results

A few years back, scientists at the biotechnology company Amgen set out to replicate 53 landmark studies that argued for new approaches to treat cancers using both existing and new molecules. They were able to replicate the findings of the original research only 11 percent of the time.

Science has a reproducibility problem. And the ramifications are widespread... Read the article:


Retour la liste des newsletters